A Study of KW-6356 in Subjects With Early Parkinson's Disease
Completed
Kyowa Hakko Kirin Company, Limited
Phase 2
The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's
disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score
between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
A Study of KW-6356 in Subjects With Early Parkinson's Disease
Completed
Kyowa Kirin Co., Ltd.
Phase 2
The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's
disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score
between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
Completed
Kyowa Hakko Kirin Co., Ltd
Phase 2
The primary objective of this study is to determine the recommended dose and evaluate the
effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the
change from baseline in Movement disorder society-unified Parkinson's disease rating
scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's
disease on treatment with Levodopa-containing preparations as an adjunctive therapy.
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
Completed
Kyowa Kirin Co., Ltd.
Phase 2
The primary objective of this study is to determine the recommended dose and evaluate the
effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the
change from baseline in Movement disorder society-unified Parkinson's disease rating
scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's
disease on treatment with Levodopa-containing preparations as an adjunctive therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
